Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Chen, Juying; Wu, Xiaozhe; Wang, Hongzhe; Lian, Xiaoshan; Li, Bing; Zhan, Xiangbo

Chen, Juying; Wu, Xiaozhe; Wang, Hongzhe; Lian, Xiaoshan; Li, Bing; Zhan, Xiangbo.

Afiliação

Chen J; Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China.
Wu X; Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China.
Wang H; Department of oncology, Shanghai Jiahui International Hospital, Shanghai, China.
Lian X; Department of Pharmacy, Shenzhen New Frontier United Family Hospital, Shenzhen China.
Li B; Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China.
Zhan X; Department of gynecology, Guangzhou Concord Cancer Center, Guangzhou, China.

Curr Comput Aided Drug Des ; 2023 Sep 07.

Article em En | MEDLINE | ID: mdl-37691198

Palavras-chave

Niraparib; Olaparib; PARP inhibitors; Rucaparib; Veliparib; network meta-analysis; ovarian cancer; systematic review

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Revista: Curr Comput Aided Drug Des Assunto da revista: FARMACOLOGIA / INFORMATICA MEDICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google